3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
3
Completed
2
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Extranodal NK-T-Cell
1
Enteropathy-Associated T-Cell Lymphoma
1
Burkitt Lymphoma
1
Interventions
Dexamethasone
14
Rituximab
6
Cytarabine
5
venetoclax
4
Lenalidomide
4
Bortezomib
4
Bendamustine Hydrochloride
4
selinexor
3
pomalidomide
3
pembrolizumab
3
ibrutinib
3
fludarabine
3
carfilzomib
3
Paclitaxel
3
Gemcitabine
3
Drug Therapy
3
Cyclophosphamide
3
Calcium Dobesilate
3
ixazomib
2
gilteritinib
2
fludarabine phosphate
2
elotuzumab
2
daratumumab
2
belinostat
2
Tablets
2
Surveys and Questionnaires
2
Panobinostat
2
Oxaliplatin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Recurrence
×
duvelisib
×
Clear all
NCT03370185
2023-02-28
BRIO
SecuraBio
Phase 2
Withdrawn